Glucagon-like peptide-1 receptor agonists during pregnancy and lactation Authors: Jonathan S. Zipursky, Tali Bogler, Cynthia Maxwell Published: 2024 Glucagon-like peptide-1 receptor agonists (GLP1RAs) are used to treat diabetes, obesity, and polycystic ovarian syndrome (PCOS) Semaglutide, liraglutide, lixisenatide, dulaglutide, and tirzepatide are the current GLP1RAs available in Canada. These are approved for the treatment of type 2 diabetes and obesity and have been used as off-label treatment for PCOS. Systematic reviews suggest that GLP1RAs can improve the spontaneous pregnancy rate, menstrual cyclicity, insulin sensitivity, and anthropometric outcomes (e.g., body mass index, weight) among patients with PCOS.1,2 Patients should stop taking GLP1RAs 1–2 months before a planned pregnancy Preclinical animal studies have shown teratogenicity at doses similar to those used in humans.3 Offspring of pregnant animals exposed to GLP1RAs have shown skeletal abnormalities and reductions in fetal weight and growth. Clinicians should counsel patients to use contraception while taking GLP1RAs. Expert opinion advises that patients stop GLP1RAs before pregnancy (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.240768/tab-related-content). No association between GLP1RAs and congenital malformations has been shown in humans Data are limited. Two small observational studies suggest no increased risk of major congenital malformations among infants born to females exposed to GLP1RAs (n = 168; n = 938) in early pregnancy or before conception.4,5 Withdrawal of GLP1RAs can lead to rebound weight gain Stopping GLP1RAs can lead to regaining around two-thirds of previous weight loss within a year.6 Obesity is associated with adverse pregnancy outcomes including gestational diabetes, hypertensive disorders, and pregnancy loss. Patients should work with their health care providers to strive for optimal weight before pregnancy and appropriate gestational weight gain. Lactating patients should avoid taking GLP1RAs Given that GLP1RAs are large protein molecules, they are unlikely to transfer to breast milk in high concentrations (Appendix 1). Any amount ingested via breast milk is likely to be degraded by proteases in the child’s stomach. However, given a paucity of human data on their safety during lactation, experts suggest that GLP1RAs should be avoided while breastfeeding. Supplementary Information